Novel blood‐based proteomic signatures across multiple neurodegenerative diseases DOI Creative Commons
Rory Durcan, Amanda Heslegrave,

Peter G. Swann

и другие.

Alzheimer s & Dementia, Год журнала: 2025, Номер 21(3)

Опубликована: Март 1, 2025

Abstract INTRODUCTION Blood‐based biomarkers have the potential to support early and accurate diagnoses of neurodegenerative diseases, which are sensitive molecular pathology predictive outcome. We evaluated a novel multiplex proteomic method in people with diverse diseases. METHODS Serum from Alzheimer's disease ( N = 36), Lewy body dementia 34), frontotemporal progressive supranuclear palsy 36) age‐matched controls 30) was analyzed nucleic acid linked immuno‐sandwich assay (NULISA) central nervous system panel (≈ 120 analytes) inflammation (250 analytes). Biomarkers were compared across groups included as predictors survival. RESULTS The NULISA panels demonstrated high sensitivity reliability for detecting multiple disorders. There condition‐specific biomarkers, while neurofilament light chain, corticotropin‐releasing hormone, CD276, data‐driven pattern significant transdiagnostic outcome predictors. DISCUSSION approach supports differential diagnosis target identification, prognostically informative dementia‐related biomarkers. Highlights tested technology serum samples. results single molecule array (Simoa) plasma assays phosphorylated tau (p‐tau)217, p‐tau231, chain (NfL), glial fibrillary acidic protein, finding strong correlations. Increased levels NfL identified all patient most elevated (FTD) (PSP) cohorts, p‐tau epitopes markers patients (AD) dementia. Patients FTD PSP showed upregulation many markers, AD. found NfL, immune signatures clinical outcomes (survival rates).

Язык: Английский

Novel blood‐based proteomic signatures across multiple neurodegenerative diseases DOI Creative Commons
Rory Durcan, Amanda Heslegrave,

Peter G. Swann

и другие.

Alzheimer s & Dementia, Год журнала: 2025, Номер 21(3)

Опубликована: Март 1, 2025

Abstract INTRODUCTION Blood‐based biomarkers have the potential to support early and accurate diagnoses of neurodegenerative diseases, which are sensitive molecular pathology predictive outcome. We evaluated a novel multiplex proteomic method in people with diverse diseases. METHODS Serum from Alzheimer's disease ( N = 36), Lewy body dementia 34), frontotemporal progressive supranuclear palsy 36) age‐matched controls 30) was analyzed nucleic acid linked immuno‐sandwich assay (NULISA) central nervous system panel (≈ 120 analytes) inflammation (250 analytes). Biomarkers were compared across groups included as predictors survival. RESULTS The NULISA panels demonstrated high sensitivity reliability for detecting multiple disorders. There condition‐specific biomarkers, while neurofilament light chain, corticotropin‐releasing hormone, CD276, data‐driven pattern significant transdiagnostic outcome predictors. DISCUSSION approach supports differential diagnosis target identification, prognostically informative dementia‐related biomarkers. Highlights tested technology serum samples. results single molecule array (Simoa) plasma assays phosphorylated tau (p‐tau)217, p‐tau231, chain (NfL), glial fibrillary acidic protein, finding strong correlations. Increased levels NfL identified all patient most elevated (FTD) (PSP) cohorts, p‐tau epitopes markers patients (AD) dementia. Patients FTD PSP showed upregulation many markers, AD. found NfL, immune signatures clinical outcomes (survival rates).

Язык: Английский

Процитировано

1